Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab)

被引:45
作者
Kain, S [1 ]
Copeland, TS [1 ]
Leahy, MF [1 ]
机构
[1] Fremantle Hosp, Dept Haematol, Fremantle, WA, Australia
关键词
rituximab; refractory autoimmune (acquired) haemophilia; factor VIII inhibitor;
D O I
10.1046/j.1365-2141.2002.03835_5.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:578 / 578
页数:1
相关论文
共 7 条
[1]  
Ahrens N, 2001, BRIT J HAEMATOL, V114, P244
[2]   HUMAN-B LYMPHOCYTES - PHENOTYPE, PROLIFERATION, AND DIFFERENTIATION [J].
BANCHEREAU, J ;
ROUSSET, F .
ADVANCES IN IMMUNOLOGY, 1992, 52 :125-262
[3]  
KARWAL MW, 2001, BLOOD S1, V98
[4]   IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab [J].
Levine, TD ;
Pestronk, A .
NEUROLOGY, 1999, 52 (08) :1701-1704
[5]  
Sparling TG, 2001, CAN MED ASSOC J, V164, P1405
[6]   Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura [J].
Stasi, R ;
Pagano, A ;
Stipa, E ;
Amadori, S .
BLOOD, 2001, 98 (04) :952-957
[7]  
WIESTNER A, 2001, BLOOD S1, V98